{"id":250849,"date":"2013-07-26T11:47:37","date_gmt":"2013-07-26T15:47:37","guid":{"rendered":"http:\/\/www.eugenesis.com\/lifemap-sciences-announces-release-of-lifemap-discovery-version-1-2-with-extensive-stem-cell-therapy-data\/"},"modified":"2013-07-26T11:47:37","modified_gmt":"2013-07-26T15:47:37","slug":"lifemap-sciences-announces-release-of-lifemap-discovery-version-1-2-with-extensive-stem-cell-therapy-data","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/lifemap-sciences-announces-release-of-lifemap-discovery-version-1-2-with-extensive-stem-cell-therapy-data.php","title":{"rendered":"LifeMap Sciences Announces Release of LifeMap Discovery\u2122 Version 1.2 With Extensive Stem Cell Therapy Data"},"content":{"rendered":"<p><p>    ALAMEDA, Calif.--(BUSINESS    WIRE)--LifeMap Sciences, Inc. announced today    the release of LifeMap Discovery version 1.2    (discovery.lifemapsc.com).    LifeMap Discovery is a state-of-the-art roadmap of    embryonic development and stem cell biology. The product    integrates embryonic development and stem cell biology,    molecular, cellular, anatomical, and disease-related    information, and provides data-mining capabilities and    bioinformatics applications. As such, it is a unique and    powerful tool for research and discovery in multiple    disciplines, including stem cell biology, developmental biology    and disease mechanisms and etiology.  <\/p>\n<p>      LifeMap Discovery version 1.2 provides enhanced features      related to stem cell therapeutic development    <\/p>\n<p>    LifeMap Discovery is a key component in LifeMaps    integrated database suite, a discovery platform for biomedical    and stem cell research, which also includes    GeneCards, the leading human gene    database, and MalaCards, the human disease database.  <\/p>\n<p>    LifeMap Discovery version 1.2 new features and    information include the following:  <\/p>\n<p>    LifeMap Discovery version 1.2 provides enhanced    features related to stem cell therapeutic development, said    Ronit Shtrichman, Ph.D., MBA, Vice President of Biology at    LifeMap Sciences. This version includes substantially upgraded    information about stem cells with potential therapeutic    applications and stem cell differentiation protocols. It also    enables researchers to identify genes specifically expressed    during embryonic development and stem cells differentiation,    providing the means to generate desired cell types for    therapeutic applications.  <\/p>\n<p>    The extensive coverage of the stem cell therapy pipeline and    high throughput gene expression data are significant steps    forward in developing our premium model, and are of significant    interest to companies developing cell-based therapies. Coupled    with the commercial offering of recombinant proteins and    PureStem progenitors, it is an important milestone for    commercialization of the LifeMap Discovery platform,    stated Yaron Guan-Golan, Head of Marketing at LifeMap Sciences.  <\/p>\n<p>    About LifeMap Sciences, Inc.  <\/p>\n<p>    LifeMap Sciences (www.lifemapsc.com)    core technology and business is based on the LifeMap Integrated    Biomedical Knowledgebase, the discovery platform for biomedical    and stem cell research. This web-based platform includes    GeneCards, the leading human gene    compendium; LifeMap Discovery, the embryonic    development, stem cell research and regenerative medicine    compendium; and MalaCards, the human disease compendium.    According to Google Analytics, the sites have generated more    than 2,000,000 unique visitors with more than 13,000,000 page    views, from more than 3,000 universities, institutions and    biomedical companies in the past 12 months.  <\/p>\n<p>    Via LifeMap BioReagents, LifeMap offers leading edge    reagents to researchers in academia, research hospitals, and    biotech and pharma companies. LifeMap is BioTimes principal    marketing subsidiary for research products, including    PureStem human progenitor cells, PureStem    packages, clinical and research grade human embryonic stem cell    (hES) lines, culture media, and cell differentiation kits. The    eCommerce portal also offers select recombinant proteins,    including growth factors, signaling molecules, differentiation    factors, cytokines and chemokines that complement    BioTimeresearch product lines.  <\/p>\n<p>    In therapeutic discovery collaboration with BioTime, LifeMaps    scientists utilize the Integrated Biomedical Knowledgebase to    aid in the development of BioTimes proprietary library of more    than 200 PureStem human progenitor cell types into    products for the treatment of human diseases, especially    degenerative diseases that might be treatable with cell    replacement therapies. A bioinformatics platform developed by    LifeMap is used to select the PureStem cells that are    most likely to be useful in developing cell-based regenerative    medicine therapies for a wide range of diseases.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read the original:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\/news\/home\/20130726005150\/en\/LifeMap-Sciences-Announces-Release-LifeMap-Discovery\u2122-Version\" title=\"LifeMap Sciences Announces Release of LifeMap Discovery\u2122 Version 1.2 With Extensive Stem Cell Therapy Data\">LifeMap Sciences Announces Release of LifeMap Discovery\u2122 Version 1.2 With Extensive Stem Cell Therapy Data<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> ALAMEDA, Calif.--(BUSINESS WIRE)--LifeMap Sciences, Inc. announced today the release of LifeMap Discovery version 1.2 (discovery.lifemapsc.com) <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/lifemap-sciences-announces-release-of-lifemap-discovery-version-1-2-with-extensive-stem-cell-therapy-data.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[25],"tags":[],"class_list":["post-250849","post","type-post","status-publish","format-standard","hentry","category-stem-cell-therapy"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/250849"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=250849"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/250849\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=250849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=250849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=250849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}